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Summary We studied all cases presenting during life with carcinoma of the bronchus and registered at the
Yorkshire Regional Cancer Registry 1976- 1983. During this period fibreoptic bronchoscopy became more
widely available in the region, and multiple drug chemotherapy became first line treatment for small cell
carcinoma. Although there was little change in the overall incidence of lung cancer during the study period,
the proportion of females increased by 4.8% and the mean age at presentation rose by 2.3 years. The
histological confirmation rate rose by 29% from 45% to 58%. The proportion of patients with small cell
carcinoma treated by chemotherapy increased from 17% to 39%. With this exception therapeutic intervention
rates were unaltered. The prognosis of patients with small cell carcinoma treated by chemotherapy improved,
particularly so for those less than 60 years. There was a consistent trend for an overall improvement in
survival in other groups, and this was significant for those aged 70 and over where it appeared to be related to
more appropriate management of squamous cell carcinoma. We conclude from this regional study that
increased diagnostic activity in District General Hospitals has allowed an improvement in prognosis both for
patients with small cell carcinoma treated by chemotherapy, and in patients over 70 with non-small cell cancer.
These trends can be expected to continue over the next few years.
In the 1970s there were two major developments in the
management of lung cancer. First, fibreoptic bronchoscopy
became more widely available (Simpson et al., 1986), and
second, chemotherapy was established as first-line treatment
for patients with small cell lung cancer (MRC Lung Cancer
Working Party, 1979).
Fibreoptic bronchoscopy is now routinely available to
91% of chest physicians, and is available in 88% of district
hospitals in England and Wales 'Muers et al., 1988; BTS
Working Party of the Regional Representatives Committee,
1987). Grant (1986) has questioned the justification of this
investigation in elderly patients with a clinical diagnosis of
carcinoma, but Knox ct al. (1988) and Macfarlane et al.
(1981) have shown its value in those over the age of 80.
However, it is not known whether fibreoptic bronchoscopy
has produced a detectable change in the treatment practice or
patient survival in the general population, as opposed to
individual specialist centres.
Treatment of small cell carcinoma with chemotherapy has
increased as controlled trials have shown an improvement in
survival, with an extension of life of about 6-12 months in
responders (Green et al., 1969; MRC Lung Cancer Working
Party, 1983; Souhami et al., 1984). However, because these
controlled trials have usually been performed in centres with
a particular interest in chemotherapy, it is not known wheth-
er the prognosis of routinely treated patients has improved.
It is well known that the average age at presentation with
lung cancer is rising (Coggan & Acheson, 1983). We
hypothesised that, because of this, more elderly patients in
our region have had surgical treatment in recent years. How-
ever, there was again no evidence to date that this policy had
produced a survival improvement.
In order to study the impact of these recent developments
in lung cancer management, we have studied all the patients
with lung cancer registered during life by the Yorkshire
Regional Cancer Registry during the period 1976-1983.
Methods
The Yorkshire Regional Cancer Registry records details of
all subjects with cancer in the Yorkshire Region of the
National Health Service. This region includes the counties of
North and West Yorkshire and Humberside. It includes the
conurbations around Leeds and Bradford, the cities of Hull
and York, the Pennine towns of Halifax and Huddersfield,
and large rural areas in North and East Yorkshire. Registra-
tion data are provided by the clerical staff in all hospitals
where cancer patients are treated and from hospital
pathology departments for all histologically confirmed
cancers. We studied all patients registered during life in the
period 1976-1983. Death certificate registrations were ex-
cluded, except for the calculation of incidence, as they could
not contribute to the survival analysis.
Diagnosis
Cases were divided histologically by the recorded diagnosis,
which was confirmed by the copies of histological reports
sent independently from the laboratories in the region. Four
diagnostic categories were recognised: (1) squamous cell car-
cinoma including large epidermoid tumours; (2) small cell
carcinoma; (3) adenocarcinoma, other histologically defined
types, histologically or cytologically confirmed malignancy,
type not defined; (4) clinical diagnosis, without histological
or cytological confirmation.
Treatment
Four treatment categories were accepted: (1) surgery (with
intention of radical excision); (2) chemotherapy; (3)
radiotherapy, radical or palliative; (4) 'no treatment', includ-
ing non-radical surgery, hormone therapy and other pal-
liative measures.
All patients were put into a single diagnostic and a single
treatment category. Patients who had multiple therapy were
considered as though their treatment category was the
highest in the order above, so that, for example, surgery
might include chemotherapy, radiotherapy or both, while
chemotherapy might include radiotherapy, but not surgery.
Statistics
Survival was calculated from the date of registration, the
end-point being death from any cause. Kaplan-Meier curves
generated by the PIL program of the statistical package
BMDP were used for survival analysis with the Mantel-Cox
statistic being used to test the equality of such curves.
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Results
General
A total of 20,155 cases of carcinoma of the bronchus were
registered in Yorkshire before death between 1976 and 1983.
The numbers varied between 2,360 and 2,629 per year, with
no consistent trend. However, over the 8 years there was an
increase in the mean age at presentation during life of 2.3
years for all subjects (Figure 1).
Female cases increased from 515 (21.8%) in 1976 to 668
(26.6%) in 1983. When death certificate notifications
representing 9.8% of the total in 1976 and 7.5% in 1983 are
included, the proportion of females remains the same at
21.7% in 1976 and 26.5% in 1983. The overall male
incidence varied between 114.0 and 124.8 per 100,000.
The histological confirmation rate rose progressively from
45.4% in 1976 to 58.4% in 1983 (Figure 2), and the mean
age of confirmed cases rose progressively from 62.9 to 65.8
years (Figure 2). Although small cell carcinoma was some-
what more prevalent in younger patients, representing about
one-third of those under 60, and only a quarter of those aged
70 or more, the overall ratio of small cell to squamous cell
remained about 3:7 throughout the period (Figure 3).
The increased diagnostic activity with an increasing mean
age of those histologically confirmed, resulted in the number
of patients known to have squamous cell carcinoma increas-
ing by 47% from 484 in 1976 to 712 in 1983, with an increase
of 2.9 years in their mean age.
Similarly the numbers known to have small cell carcinoma
also increased by 47% from 209 to 308 with an increase of
3.9 years in the mean age. The increase in the numbers of
histologically confirmed cases was largely in those aged 70
and over for squamous cell carcinoma and 60 or over the
small cell carcinoma, with little change in the histological
confirmation rate below the age of 60.
Squamous cell carcinoma
During the period of observation there was an increase in the
proportion of patients with confirmed squamous carcinoma
who were actively managed, from 52.9% in 1976 to more
than 60% in 1978 and subsequently. This increase in active
management (radical surgery and radiotherapy, with
chemotherapy in less than 7%) occurred although the
number of patients over 70 years also increased from 114
(23.6%) in 1976 to 270 (37.9%) of the total in 1983. These
older patients showed an improved survival over the peroid of
observation (P<0.012), although this improvement was not
enough to establish a significant trend in the prognosis for
the group as a whole.
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Figure I All cases of lung cancer registered during life
1976-1983. Upper panel, mean age at presentation. Lower panel,
numbers of male and female patients.
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Figure 2 Histologically confirmed diagnoses 1976- 1983. Upper
panel, mean age of patients. Lower panel, confirmed cases as
proportion of total registered.
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Figure 3 Confirmed small cell and squamous cell carcinoma
1977-1983. Upper panel, mean age at presentation. Lower panel,
number of cases.
Small cell carcinoma
Figure 4 shows the survival curves for all the cases of small
cell carcinoma, by year, 1976-1983. It can be seen that the
prognosis to 9 months showed a considerable improvement
during the period.
The reason for this is seen in Table I, which shows the
number and proportion ofpatients treated with chemotherapy.
As this proportion increased, so the prognosis improved,
with a particularly large change in median survival between
1979 and 1980, and an overall improvement in the percentage
of patients surviving to 9 months. The survival difference
lessened subsequently, but most long-term survivors had been
treated with chemotherapy.
Figure 5 shows the survival to 9 months for the years
1980-1983 of three different age cohorts: <60 years, 60-69
years, and >,70 years. Better survival after chemotherapy
than radiotherapy was seen in patients under 60, but there
was no such difference in the older patients. As expected, the
prognosis of older treated patients was worse than the
younger, and approached the 'no treatment' group in the
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Figure 4 Survival curves to 9 months of all registered patients
with small cell carcinoma 1976-1983.
Table I Small cell carcinoma
Median survival % survival
(days) at 9 months
Chemotherapy Chemotherapy All Chemotherapy All
Year Total patients (%) patients patients patients patients
1976 209 36 (17) 107 89 19 18
1977 199 39 (20) 82 58 13 12
1978 196 41(21) 96 83 22 16
1979 247 54 (22) 86 72 13 16
1980 248 72 (29) 178 86 24 23
1981 263 96 (37) 170 99 31 21
1982 314 130 (41) 218 94 40 26
1983 308 121 (39) 175 88 36 25
Median and nine-month survival in all subjects and patients treated
with chemotherapy, 1976-1983. Columns show year, total number of
registrations, number and per cent patients treated with chemotherapy,
median survival in days for chemotherapy treated patients and all
patients, per cent9-month survivalchemotherapy treatedpatientsandall
patients.
over 70s. At all age groups there were a very small number
of long-term survivors treated by radical surgery. One hun-
dred and thirty-seven patients were operated on, averaging 17
per annum (range 14-25). Fifteen (11%) of the operated
cases were alive at 2 years. The 2-year survival of the small
cell carcinoma patients improved from 2% to 8% between
1976 and 1983 (P = 0.004). These patients had been treated
by chemotherapy or, occasionally, by surgery.
Other confirmed histological groups
These remained about 17% of the total throughout the
period. The 2-year survival varied between 7.1% and 11.7%
with no consistent trend. Within this number we found no
evidence of a significant increase in adenocarcinomas
identified during the 8-year period studied. Likewise, there
was no significant trend in the prognosis of these tumours.
Histologically non-confirmed
There was no change in the poor prognosis of these patients
in the study period. The 2-year survival was about 4%
throughout. This poor prognosis suggests that the majority
were indeed lung cancer, despite the absence of histological
confirmation. The number given chemotherapy without a
confirmed diagnosis fell from 98 (7.6%) in 1976 to 32 (3.1%)
in 1983.
Survival ofthe whole population with lung cancer
Examination of the 2-year survival data for the whole
population (Figure 6) confirms a trend to improved prog-
nosis between 1976 and 1983. For the patients over 70 P for
the trend is 0.012 and for those under 60 P = 0.057. The
impact of an active treatment policy for patients over 70 is
seen in Figure 7, where the trend to improved survival is
highly significant (P = 0.01).
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Figure 5 Survival to 9 months of all registered small cell car-
cinoma patients analysed by age and treatment modality. Note:
the number of surgically treated cases is small.
The median survival for the whole population did not
change during the period of observation. The improved 2-
year survival figures therefore mean that increasing numbers
of better prognosis patients were treated during the period,
and more long-term survivors resulted from this selection
and treatment policy. In 1983 there were 85 survivors at 2
years following surgery, which was 35.3% of those operated
upon.
Discussion
In this study we attempted to analyse the effect upon the
survival of lung cancer patients throughout a diverse region
of the UK, of better anatomical and histological diagnosis by
fibreoptic bronchoscopy, modern multiple drug
chemotherapy for small cell lung cancer, and surgery for
suitable patients over the age of 70.582 C.K. CONNOLLY et al.
25.00 r-
Treated
.- - Untreated
20.00
15.001-
10.00F
5.00
0.00
.......,.-...
_
1979 1980
Years
1981 1982 1983
survival for all cases analysed by
1976 1977 1978
Figure 6 Percentage 2-year
year at presentation.
25.00 r
Treated
.---- Untreated
20.00K
1500-
10.00
5.00
1976 1977 1978 1979 1980 1981 1982 1983
Years
Figure 7 Percentage of 2-year survival for all cases presenting
over age 70 years: upper curve actively treated patients; lower
curve symptomatic treatment.
Epidemiology
The rise we noted in the mean age at presentation of patients
with lung cancer and the rise in the percentage of female
patients are similar to trends now well recognised and reflect
changing patterns of cigarette smoking established 20 years
ago (Coggon & Acheson, 1983; Edinburgh Lung Cancer Group,
1987; Hande & Des Prez, 1983). Although small cell carcinoma
is known to be more common among younger patients (Edin-
burgh Lung Cancer Group, 1987), and we confirm this, the
increase in mean age of our population was not accompanied by
a significant proportional change in the small cell/squamous
ratio. Thus we have no evidence so far that small cell car-
cinoma is becoming a significantly rarer tumour in Britain at
the present time; conversely, a higher rate of histological
diagnosis is likely to identify increasing numbers.
Histological verification
The particular reason for histological verification is first to
allow correct information to be given to patients, second to
allow a more accurate prognosis, and third to allow more
appropriate therapy. Fibreoptic bronchoscopy can also be
used to assess operability, and its use has been parallelled by a
fall in the rate and availability of rigid bronchoscopy in the
UK (British Thoracic Society, 1987; Muers et al., 1988). In our
study, the effect of this activity was to raise the rate of
histological confirmation by 29% over the 6-year period, from
45% to 58% of all cases. This is still a lower rate than in
smaller series from other centres, such as Edinburgh (Edin-
burgh Lung Cancer Group, 1987). It is likely to increase
further in our region, and probably elsewhere in the UK.
Fibreoptic bronchoscopy is practised by more recently quali-
fied respiratory consultants, and in the Yorkshire region seven
of 21 respiratory physicians were replaced in this survey period
and since 1983 10 more new appointments have been made.
Small cell carcinoma
The benefits shown in controlled trials of treatment with
chemotherapy (Green et al., 1969; MRC Lung Cancer Work-
ing Party, 1979, 1983; Souhami et al., 1984) are now being
reflected in the survival experience of patients throughout our
region. Survival to 9 months, but not the median survival,
has increased (Table I). This seems to be because more
patients well enough for treatment are having chemotherapy,
but the untreated, probably older, patients have a very bad
prognosis. It is well recognised that the effect of chemo-
therapy for small cell lung cancer has reached a plateau
(Klastersky, 1988) and there may not be a further increase in
survival now for some time, although chemotherapy regimens
may be simplified and better use of prognostic factors may
limit treatment to those destined to survive long enough to
show such benefit (Vincent et al., 1987).
Methods
Registry data was used for this analysis. We recognise that
the registry does not hold records for all patients with lung
cancer in Yorkshire, but comparison of the registry figures
with the standardised incidence rates from the OPCS (1979,
1981) revealed that the Registry data recorded a higher than
expected rate for males, and the expected rate for females
(YRCO, 1985). This is evidence that the Registry holds a
largely complete record of bronchial carcinoma in the York-
shire region. Our survival data are open to two criticisms.
First, we have not included survival data for patients
registered at death. However, the percentage of cases so
excluded was not large (9.8% in 1976 falling to 7.5% in
1983), and we do not think their absence will have changed
the conclusions of our study. Second, there is a possibility
that the improvement in survival we have observed is due to
faster reporting or registering of cases. However, we do not
think this is the case, since then the improvement in survival
would not have been mainly confined to particular age
groups as we have seen.
Squamous cell lung cancer
Doubts have been expressed about the ethical justification for
both the investigation and intensive treatment of older
patients with carcinoma of the bronchus (Grant, 1986). This
study amply justifies the increased diagnostic activity, as the
principal beneficiaries of the change in practice in the years
of the study were patients with squamous cell carcinoma
aged 70 or over. The rate of surgical intervention in
squamous cell carcinoma as a whole was little changed des-
pite the increases in age, and survival was not compromised.
There is no support in the figures here for the view that a
patient should not be operated upon over the age of 70.
Conclusion
This cancer registry study has shown modest improvements
in prognosis in some groups of patients with lung carcinoma
as a result of the application of modern methods of diagnosis
and treatment. There are grounds for the belief that these
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trends will continue as the techniques become even more
widely available and applied within District General Hos-
pitals in Britian. Our findings support the view that there is a
need for all patients with carcinoma of the lung to be refer-
red to respiratory physicians for full evaluation and advice
about appropriate management.
Thanks are due to Professor C.A. Joslin and the Yorkshire Regional
Cancer Registry for permission to publish the results, to the staff of
the Registry for their help and to Mrs S.P. Patten and Miss S.A.
Tate for the typing of this paper. Members of the Thoracic Group of
the Yorkshire Regional Cancer Organisation are thanked for their
comments.
References
BRITISH THORACIC SOCIETY (1987). Report for the British Thoracic
Society by a Working Party of the Regional Representatives
Committee. British Thoracic Society: London.
COGGON, D. &ACHESON. E.D. (1983). Trends in lungcancer mortality.
Thorax, 38, 721.
EDINBURGH LUNG CANCER GROUP (1987). Patients presenting with
lung cancer in South East Scotland. Thorax, 42, 853.
GRANT, I.W.B. (1986). Hazards of bronchoscopy (editorial). Br. Med.
J., 293, 286.
GREEN, R.A., HUMPHREY. E., CLOSE, H. & PATNO. M.E. (1969).
Alkylating agents and bronchogenic carcinoma. Am. J. Med., 46,
516.
HANDE, K.R. & DES PREZ, R.M. (1983). Non-small cell cancer of the
lung. In Recent Advances in Respiratory Medicine3, Flenley, D.C. &
Petty, T.L. (eds) p. 205. Churchill Livingstone: Edinburgh.
KLASTERSKY, J. (1988). Therapy of small cell Lung cancer: anything
new? Eur. J. Clin. Oncol., 24, 107.
KNOX, A.J., MASCIE-TAYLOR, B.H. & PAGE, R.L. (1988). Fibreoptic
bronchoscopy intheelderly: 4yearsexperience. Br. J. Dis. Chest,82,
290.
MACFARLANE, J.T., STORR, A., WARD, M.J. & RODERICK-SMITH,
W.H. (1981). Safety, usefulness and acceptability iffibreoptic bron-
choscopy in the elderly. Age Ageing, 10, 127.
MEDICAL RESEARCH COUNCIL LUNG CANCER WORKING PARTY
(1979). Radiotherapy alone or with chemotherapy in the treatment
of small cell carcinoma of the lung. Br. J. Cancer, 40, 1.
MEDICAL RESEARCH COUNCIL LUNG CANCER WORKING PARTY
(1983). Cytotoxic chemotherapy before and after radiotherapy
compared with radiotherapy followed by chemotherapy in the
treatment ofsmall-cell carcinoma ofthe bronchus: the results up to
36 months. Br. J. Cancer, 48, 755.
MUERS, M.F., CHAPPELL, A.G., FAIRBROTHER, M. el al. (1988).
Facilities for the diagnosis of respiratory disease in the UK. J. R.
Coll. Ph/'s., 22, 180.
OPCS(1979). Cancer statistics: registrations, England and Wales. Office
of Population Censuses and Surveys. Series MBE No. 11. HMSO:
London.
OPCS (1981). Cancer statistics: registrations, England and Wales. Office
ofPopulation Censuses and Surveys. Series MBE No. 13. HMSO:
London.
SIMPSON, F.G., ARNOLD, A.G., PURVIS, A. cl al. (1986). Postal survey
of bronchoscopic practice by physicians in the United Kingdom.
Thorax, 41, 311.
SOUHAMI, R.L.,GEDDES, D.M., SPIRO, S.G. ctal. (1984). Radiotherapy
in small cell cancer of the lung treated with combination
chemotherapy: a controlled trial. Br. Med. J., 288, 1643.
VINCENT, M.D., ASHLEY, S.E. & SMITH. I.E. (1987). Prognostic factors
in small cell lung cancer: a simple prognostic index is better than
conventional staging. Eur. J. Cancer Clin. Oncol., 23, 1589.
YRCO (1985). Report for the year 1985: Cancer statistics for 1978 -83.
Yorkshire Regional Cancer Registry: Leeds.